ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    facet.materialart.
    Unknown
    Cancer: Antibodies regulate antitumour immunity (2015)
    Nature Publishing Group (NPG)
    Details
    Publication Date: 2015-04-30
    Description: 〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Zitvogel, Laurence -- Kroemer, Guido -- England -- Nature. 2015 May 7;521(7550):35-7. doi: 10.1038/nature14388. Epub 2015 Apr 29.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Gustave Roussy Comprehensive Cancer Center, 94805 Villejuif, France. ; Cordeliers Research Center of the University Paris Descartes, 75006 Paris, France, and at the Pole de Biologie, Hopital Europeen Georges Pompidou, Paris.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/25924066" target="_blank"〉PubMed〈/a〉
    Print ISSN: 0028-0836
    Electronic ISSN: 1476-4687
    Topics: Biology , Chemistry and Pharmacology , Medicine , Natural Sciences in General , Physics
    Published by Nature Publishing Group (NPG)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 2
    facet.materialart.
    Unknown
    Innate or adaptive immunity? The example of natural killer cells (2011)
    American Association for the Advancement of Science (AAAS)
    Details
    Publication Date: 2011-01-08
    Description: Natural killer (NK) cells were originally defined as effector lymphocytes of innate immunity endowed with constitutive cytolytic functions. More recently, a more nuanced view of NK cells has emerged. NK cells are now recognized to express a repertoire of activating and inhibitory receptors that is calibrated to ensure self-tolerance while allowing efficacy against assaults such as viral infection and tumor development. Moreover, NK cells do not react in an invariant manner but rather adapt to their environment. Finally, recent studies have unveiled that NK cells can also mount a form of antigen-specific immunologic memory. NK cells thus exert sophisticated biological functions that are attributes of both innate and adaptive immunity, blurring the functional borders between these two arms of the immune response.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3089969/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉   〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3089969/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Vivier, Eric -- Raulet, David H -- Moretta, Alessandro -- Caligiuri, Michael A -- Zitvogel, Laurence -- Lanier, Lewis L -- Yokoyama, Wayne M -- Ugolini, Sophie -- AI035021/AI/NIAID NIH HHS/ -- AI039642/AI/NIAID NIH HHS/ -- AI066897/AI/NIAID NIH HHS/ -- AI068129/AI/NIAID NIH HHS/ -- AI33903/AI/NIAID NIH HHS/ -- AI34385/AI/NIAID NIH HHS/ -- AI51345/AI/NIAID NIH HHS/ -- AI5716/AI/NIAID NIH HHS/ -- CA093678/CA/NCI NIH HHS/ -- CA095137/CA/NCI NIH HHS/ -- CA16058/CA/NCI NIH HHS/ -- CA68458/CA/NCI NIH HHS/ -- CA95426/CA/NCI NIH HHS/ -- R01 AI035021/AI/NIAID NIH HHS/ -- R01 AI035021-11/AI/NIAID NIH HHS/ -- R01 AI039642/AI/NIAID NIH HHS/ -- R01 AI039642-11/AI/NIAID NIH HHS/ -- R01 CA093678/CA/NCI NIH HHS/ -- R01 CA093678-10/CA/NCI NIH HHS/ -- Howard Hughes Medical Institute/ -- New York, N.Y. -- Science. 2011 Jan 7;331(6013):44-9. doi: 10.1126/science.1198687.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Centre d'Immunologie de Marseille-Luminy (CIML), Universite de la Mediterranee UM 631, Campus de Luminy, 13288 Marseille, France. vivier@ciml.univ-mrs.fr〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/21212348" target="_blank"〉PubMed〈/a〉
    Keywords: *Adaptive Immunity ; Animals ; Humans ; *Immunity, Innate ; Immunologic Memory ; Killer Cells, Natural/*immunology ; Neoplasms/immunology/therapy ; Receptors, Immunologic/immunology/metabolism ; Self Tolerance ; Virus Diseases/immunology
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Published by American Association for the Advancement of Science (AAAS)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 3
    facet.materialart.
    Unknown
    The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide (2013)
    American Association for the Advancement of Science (AAAS)
    Details
    Publication Date: 2013-11-23
    Description: Cyclophosphamide is one of several clinically important cancer drugs whose therapeutic efficacy is due in part to their ability to stimulate antitumor immune responses. Studying mouse models, we demonstrate that cyclophosphamide alters the composition of microbiota in the small intestine and induces the translocation of selected species of Gram-positive bacteria into secondary lymphoid organs. There, these bacteria stimulate the generation of a specific subset of "pathogenic" T helper 17 (pT(H)17) cells and memory T(H)1 immune responses. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram-positive bacteria showed a reduction in pT(H)17 responses, and their tumors were resistant to cyclophosphamide. Adoptive transfer of pT(H)17 cells partially restored the antitumor efficacy of cyclophosphamide. These results suggest that the gut microbiota help shape the anticancer immune response.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048947/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉   〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048947/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Viaud, Sophie -- Saccheri, Fabiana -- Mignot, Gregoire -- Yamazaki, Takahiro -- Daillere, Romain -- Hannani, Dalil -- Enot, David P -- Pfirschke, Christina -- Engblom, Camilla -- Pittet, Mikael J -- Schlitzer, Andreas -- Ginhoux, Florent -- Apetoh, Lionel -- Chachaty, Elisabeth -- Woerther, Paul-Louis -- Eberl, Gerard -- Berard, Marion -- Ecobichon, Chantal -- Clermont, Dominique -- Bizet, Chantal -- Gaboriau-Routhiau, Valerie -- Cerf-Bensussan, Nadine -- Opolon, Paule -- Yessaad, Nadia -- Vivier, Eric -- Ryffel, Bernhard -- Elson, Charles O -- Dore, Joel -- Kroemer, Guido -- Lepage, Patricia -- Boneca, Ivo Gomperts -- Ghiringhelli, Francois -- Zitvogel, Laurence -- P01 DK071176/DK/NIDDK NIH HHS/ -- P01DK071176/DK/NIDDK NIH HHS/ -- P50 CA086355/CA/NCI NIH HHS/ -- R01 AI084880/AI/NIAID NIH HHS/ -- New York, N.Y. -- Science. 2013 Nov 22;342(6161):971-6. doi: 10.1126/science.1240537.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Institut National de la Sante et de la Recherche Medicale, U1015, Equipe labellisee Ligue Nationale Contre le Cancer, Institut Gustave Roussy, Villejuif, France.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/24264990" target="_blank"〉PubMed〈/a〉
    Keywords: Adoptive Transfer ; Animals ; Anti-Bacterial Agents/administration & dosage ; Antineoplastic Agents/*therapeutic use ; Bacterial Translocation/*drug effects ; Cyclophosphamide/*therapeutic use ; Germ-Free Life ; Gram-Positive Bacteria/drug effects/physiology ; Immunologic Memory ; Immunosuppressive Agents/*therapeutic use ; Intestine, Small/*microbiology ; Lymphoid Tissue/immunology/microbiology ; Mice ; Microbiota/drug effects/*physiology ; Neoplasms/*drug therapy/*immunology ; Th17 Cells/immunology/transplantation
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Published by American Association for the Advancement of Science (AAAS)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 4
    facet.materialart.
    Unknown
    Neutralizing tumor-promoting chronic inflammation: a magic bullet? (2013)
    American Association for the Advancement of Science (AAAS)
    Details
    Publication Date: 2013-01-19
    Description: There have been substantial advances in cancer diagnostics and therapies in the past decade. Besides chemotherapeutic agents and radiation therapy, approaches now include targeting cancer cell-intrinsic mediators linked to genetic aberrations in cancer cells, in addition to cancer cell-extrinsic pathways, especially those regulating vascular programming of solid tumors. More recently, immunotherapeutics have entered the clinic largely on the basis of the recognition that several immune cell subsets, when chronically activated, foster tumor development. Here, we discuss clinical and experimental studies delineating protumorigenic roles for immune cell subsets that are players in cancer-associated inflammation. Some of these cells can be targeted to reprogram their function, leading to resolution, or at least neutralization, of cancer-promoting chronic inflammation, thereby facilitating cancer rejection.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591506/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉   〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591506/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Coussens, Lisa M -- Zitvogel, Laurence -- Palucka, A Karolina -- R01 CA155331/CA/NCI NIH HHS/ -- U54 CA163123/CA/NCI NIH HHS/ -- New York, N.Y. -- Science. 2013 Jan 18;339(6117):286-91. doi: 10.1126/science.1232227.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Cell and Developmental Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239-3098, USA. coussenl@ohsu.edu〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/23329041" target="_blank"〉PubMed〈/a〉
    Keywords: Antibodies/therapeutic use ; Breast Neoplasms/immunology/pathology ; Carcinoma, Ductal/immunology/pathology ; Chemokines/antagonists & inhibitors/immunology ; Chronic Disease ; Cytokines/antagonists & inhibitors/immunology ; Disease Progression ; Female ; Humans ; Immunotherapy/*methods ; Inflammation/*immunology/pathology/*therapy ; Leukocytes/*immunology ; Myeloid Cells/immunology ; Neoplasms/*immunology/pathology/*therapy
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Published by American Association for the Advancement of Science (AAAS)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 5
    facet.materialart.
    Unknown
    Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice (2011)
    American Association for the Advancement of Science (AAAS)
    Details
    Publication Date: 2011-12-17
    Description: Antineoplastic chemotherapies are particularly efficient when they elicit immunogenic cell death, thus provoking an anticancer immune response. Here we demonstrate that autophagy, which is often disabled in cancer, is dispensable for chemotherapy-induced cell death but required for its immunogenicity. In response to chemotherapy, autophagy-competent, but not autophagy-deficient, cancers attracted dendritic cells and T lymphocytes into the tumor bed. Suppression of autophagy inhibited the release of adenosine triphosphate (ATP) from dying tumor cells. Conversely, inhibition of extracellular ATP-degrading enzymes increased pericellular ATP in autophagy-deficient tumors, reestablished the recruitment of immune cells, and restored chemotherapeutic responses but only in immunocompetent hosts. Thus, autophagy is essential for the immunogenic release of ATP from dying cells, and increased extracellular ATP concentrations improve the efficacy of antineoplastic chemotherapies when autophagy is disabled.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Michaud, Mickael -- Martins, Isabelle -- Sukkurwala, Abdul Qader -- Adjemian, Sandy -- Ma, Yuting -- Pellegatti, Patrizia -- Shen, Shensi -- Kepp, Oliver -- Scoazec, Marie -- Mignot, Gregoire -- Rello-Varona, Santiago -- Tailler, Maximilien -- Menger, Laurie -- Vacchelli, Erika -- Galluzzi, Lorenzo -- Ghiringhelli, Francois -- di Virgilio, Francesco -- Zitvogel, Laurence -- Kroemer, Guido -- New York, N.Y. -- Science. 2011 Dec 16;334(6062):1573-7. doi: 10.1126/science.1208347.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉INSERM, U848, Villejuif, France.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/22174255" target="_blank"〉PubMed〈/a〉
    Keywords: Adenosine Triphosphate/metabolism ; Animals ; Antineoplastic Agents/*pharmacology/therapeutic use ; Autophagy/drug effects/*physiology ; Calreticulin/pharmacology ; Cell Death/immunology ; Cell Line, Tumor ; Dendritic Cells/immunology ; Humans ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Mitoxantrone/pharmacology ; Neoplasms/drug therapy/*immunology
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Published by American Association for the Advancement of Science (AAAS)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 6
    facet.materialart.
    Unknown
    An immunosurveillance mechanism controls cancer cell ploidy (2012)
    American Association for the Advancement of Science (AAAS)
    Details
    Publication Date: 2012-09-29
    Description: Cancer cells accommodate multiple genetic and epigenetic alterations that initially activate intrinsic (cell-autonomous) and extrinsic (immune-mediated) oncosuppressive mechanisms. Only once these barriers to oncogenesis have been overcome can malignant growth proceed unrestrained. Tetraploidization can contribute to oncogenesis because hyperploid cells are genomically unstable. We report that hyperploid cancer cells become immunogenic because of a constitutive endoplasmic reticulum stress response resulting in the aberrant cell surface exposure of calreticulin. Hyperploid, calreticulin-exposing cancer cells readily proliferated in immunodeficient mice and conserved their increased DNA content. In contrast, hyperploid cells injected into immunocompetent mice generated tumors only after a delay, and such tumors exhibited reduced DNA content, endoplasmic reticulum stress, and calreticulin exposure. Our results unveil an immunosurveillance system that imposes immunoselection against hyperploidy in carcinogen- and oncogene-induced cancers.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Senovilla, Laura -- Vitale, Ilio -- Martins, Isabelle -- Tailler, Maximilien -- Pailleret, Claire -- Michaud, Mickael -- Galluzzi, Lorenzo -- Adjemian, Sandy -- Kepp, Oliver -- Niso-Santano, Mireia -- Shen, Shensi -- Marino, Guillermo -- Criollo, Alfredo -- Boileve, Alice -- Job, Bastien -- Ladoire, Sylvain -- Ghiringhelli, Francois -- Sistigu, Antonella -- Yamazaki, Takahiro -- Rello-Varona, Santiago -- Locher, Clara -- Poirier-Colame, Vichnou -- Talbot, Monique -- Valent, Alexander -- Berardinelli, Francesco -- Antoccia, Antonio -- Ciccosanti, Fabiola -- Fimia, Gian Maria -- Piacentini, Mauro -- Fueyo, Antonio -- Messina, Nicole L -- Li, Ming -- Chan, Christopher J -- Sigl, Verena -- Pourcher, Guillaume -- Ruckenstuhl, Christoph -- Carmona-Gutierrez, Didac -- Lazar, Vladimir -- Penninger, Josef M -- Madeo, Frank -- Lopez-Otin, Carlos -- Smyth, Mark J -- Zitvogel, Laurence -- Castedo, Maria -- Kroemer, Guido -- New York, N.Y. -- Science. 2012 Sep 28;337(6102):1678-84.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉INSERM, U848, Villejuif, France.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/23019653" target="_blank"〉PubMed〈/a〉
    Keywords: Animals ; Calreticulin/immunology ; Cell Line, Tumor ; Common Variable Immunodeficiency/genetics ; DNA, Neoplasm/analysis/genetics ; Endoplasmic Reticulum Stress/*immunology ; Eukaryotic Initiation Factor-2/metabolism ; Humans ; Immunocompetence ; *Immunologic Surveillance ; Mice ; Mice, Inbred BALB C ; Neoplasms/chemically induced/*genetics/*immunology ; Phosphorylation ; *Ploidies
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Published by American Association for the Advancement of Science (AAAS)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 7
    facet.materialart.
    Unknown
    CANCER. A p53-regulated immune checkpoint relevant to cancer (2015)
    American Association for the Advancement of Science (AAAS)
    Details
    Publication Date: 2015-08-01
    Description: 〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Zitvogel, Laurence -- Kroemer, Guido -- New York, N.Y. -- Science. 2015 Jul 31;349(6247):476-7. doi: 10.1126/science.aac8475.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Gustave Roussy Cancer Campus, F-94805 Villejuif, France. INSERM U1015, F-94805 Villejuif, France. Universite Paris Sud-XI, Faculte de Medecine, Le Kremlin Bicetre, France. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94805 Villejuif, France. ; Equipe 11 labellisee par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, F-75006 Paris, France. Universite Paris Descartes, Sorbonne Paris Cite, F-75006 Paris, France. Universite Pierre et Marie Curie, F-75006 Paris, France. Pole de Biologie, Hopital Europeen Georges Pompidou, AP-HP, F-75015 Paris. Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, F-94805 Villejuif, France. kroemer@orange.fr.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/26228128" target="_blank"〉PubMed〈/a〉
    Keywords: Animals ; Apoptosis/*immunology ; Female ; Humans ; Male ; Membrane Proteins/*metabolism ; Phagocytosis/*immunology ; Phosphatidylserines/*metabolism ; Tumor Suppressor Protein p53/*metabolism
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Published by American Association for the Advancement of Science (AAAS)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 8
    facet.materialart.
    Unknown
    Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1 (2015)
    American Association for the Advancement of Science (AAAS)
    Details
    Publication Date: 2015-10-31
    Description: Antitumor immunity driven by intratumoral dendritic cells contributes to the efficacy of anthracycline-based chemotherapy in cancer. We identified a loss-of-function allele of the gene coding for formyl peptide receptor 1 (FPR1) that was associated with poor metastasis-free and overall survival in breast and colorectal cancer patients receiving adjuvant chemotherapy. The therapeutic effects of anthracyclines were abrogated in tumor-bearing Fpr1(-/-) mice due to impaired antitumor immunity. Fpr1-deficient dendritic cells failed to approach dying cancer cells and, as a result, could not elicit antitumor T cell immunity. Experiments performed in a microfluidic device confirmed that FPR1 and its ligand, annexin-1, promoted stable interactions between dying cancer cells and human or murine leukocytes. Altogether, these results highlight the importance of FPR1 in chemotherapy-induced anticancer immune responses.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Vacchelli, Erika -- Ma, Yuting -- Baracco, Elisa E -- Sistigu, Antonella -- Enot, David P -- Pietrocola, Federico -- Yang, Heng -- Adjemian, Sandy -- Chaba, Kariman -- Semeraro, Michaela -- Signore, Michele -- De Ninno, Adele -- Lucarini, Valeria -- Peschiaroli, Francesca -- Businaro, Luca -- Gerardino, Annamaria -- Manic, Gwenola -- Ulas, Thomas -- Gunther, Patrick -- Schultze, Joachim L -- Kepp, Oliver -- Stoll, Gautier -- Lefebvre, Celine -- Mulot, Claire -- Castoldi, Francesca -- Rusakiewicz, Sylvie -- Ladoire, Sylvain -- Apetoh, Lionel -- Bravo-San Pedro, Jose Manuel -- Lucattelli, Monica -- Delarasse, Cecile -- Boige, Valerie -- Ducreux, Michel -- Delaloge, Suzette -- Borg, Christophe -- Andre, Fabrice -- Schiavoni, Giovanna -- Vitale, Ilio -- Laurent-Puig, Pierre -- Mattei, Fabrizio -- Zitvogel, Laurence -- Kroemer, Guido -- New York, N.Y. -- Science. 2015 Nov 20;350(6263):972-8. doi: 10.1126/science.aad0779. Epub 2015 Oct 29.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Universite Paris Descartes, Sorbonne Paris Cite, Paris, France. Universite Pierre et Marie Curie, Paris, France. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Universite Paris Descartes, Sorbonne Paris Cite, Paris, France. Universite Pierre et Marie Curie, Paris, France. Suzhou Institute of Systems Medicine, Suzhou, Jiangsu, China. Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Faculte de Medecine, Universite Paris-Saclay, Kremlin-Bicetre, France. ; Regina Elena National Cancer Institute, Rome, Italy. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Universite Paris Descartes, Sorbonne Paris Cite, Paris, France. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1015, Villejuif, France. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France. ; Department of Hematology, Oncology, and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy. ; Italian National Research Council, Institute for Photonics and Nanotechnology, Rome, Italy. ; Genomics and Immunoregulation, Life and Medical Science Center Institute, University of Bonn, Germany. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U981, Villejuif, France. ; Universite Paris Sorbonne Cite, UMRS 775, INSERM, Paris, France. INSERM U1147, Centre de Ressources Biologiques (CRB) EPIGENETIC, Paris, France. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Faculte de Medecine, Universite Paris-Saclay, Kremlin-Bicetre, France. Sotio, Prague, Czech Republic. ; Department of Medical Oncology, Centre Georges-Francois Leclerc, Dijon, France. Universite Bourgogne Franche-Comte, Dijon, France. Centre Georges Francois Leclerc, Dijon, France. ; Department of Life Sciences, University of Siena, Siena, Italy. ; Institut du Cerveau et de la Moelle Epiniere, ICM CNRS UMR 7225 - INSERM U 1127 - UPMC-P6 UMR S 1127, Equipe Neurogenetique et Physiologie Hopital de la Pitie-Salpetriere, 47, Boulevard de l'Hopital, 75013 Paris, France. ; INSERM U1147, Centre de Ressources Biologiques (CRB) EPIGENETIC, Paris, France. Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif Cedex, France. ; Faculte de Medecine, Universite Paris-Saclay, Kremlin-Bicetre, France. Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif Cedex, France. ; INSERM, U981, Villejuif, France. Department of Breast Oncology, Gustave Roussy Cancer Campus, Villejuif, France. ; University of Franche-Comte, INSERM 1098, France. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U981, Villejuif, France. Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France. Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. ; Regina Elena National Cancer Institute, Rome, Italy. Department of Biology, University of Rome "Tor Vergata," Rome, Italy. ; Universite Paris Sorbonne Cite, UMRS 775, INSERM, Paris, France. INSERM U1147, Centre de Ressources Biologiques (CRB) EPIGENETIC, Paris, France. Pole de Biologie, Hopital Europeen Georges Pompidou, AP-HP, Paris, France. ; Gustave Roussy Cancer Campus, Villejuif, France. Faculte de Medecine, Universite Paris-Saclay, Kremlin-Bicetre, France. INSERM, U1015, Villejuif, France. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France. kroemer@orange.fr laurence.zitvogel@gustaveroussy.fr. ; Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Equipe 11 Labellisee par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Universite Paris Descartes, Sorbonne Paris Cite, Paris, France. Universite Pierre et Marie Curie, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France. Pole de Biologie, Hopital Europeen Georges Pompidou, AP-HP, Paris, France. Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, 17176 Stockholm, Sweden. kroemer@orange.fr laurence.zitvogel@gustaveroussy.fr.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/26516201" target="_blank"〉PubMed〈/a〉
    Keywords: Alleles ; Animals ; Annexin A1/metabolism/pharmacology ; Anthracyclines/*therapeutic use ; Breast Neoplasms/drug therapy/immunology ; Cell Line, Tumor ; Chemotherapy, Adjuvant ; Colorectal Neoplasms/drug therapy/immunology ; Dendritic Cells/drug effects/immunology ; Female ; Humans ; Immunity, Innate/genetics ; Leukocytes/drug effects/immunology ; Mice ; Neoplasms/*drug therapy/*immunology ; Polymorphism, Single Nucleotide ; Receptors, Formyl Peptide/genetics/*physiology ; T-Lymphocytes/immunology
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Published by American Association for the Advancement of Science (AAAS)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 9
    facet.materialart.
    Unknown
    Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota (2015)
    American Association for the Advancement of Science (AAAS)
    Details
    Publication Date: 2015-11-07
    Description: Antibodies targeting CTLA-4 have been successfully used as cancer immunotherapy. We find that the antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species. In mice and patients, T cell responses specific for B. thetaiotaomicron or B. fragilis were associated with the efficacy of CTLA-4 blockade. Tumors in antibiotic-treated or germ-free mice did not respond to CTLA blockade. This defect was overcome by gavage with B. fragilis, by immunization with B. fragilis polysaccharides, or by adoptive transfer of B. fragilis-specific T cells. Fecal microbial transplantation from humans to mice confirmed that treatment of melanoma patients with antibodies against CTLA-4 favored the outgrowth of B. fragilis with anticancer properties. This study reveals a key role for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721659/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉   〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721659/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Vetizou, Marie -- Pitt, Jonathan M -- Daillere, Romain -- Lepage, Patricia -- Waldschmitt, Nadine -- Flament, Caroline -- Rusakiewicz, Sylvie -- Routy, Bertrand -- Roberti, Maria P -- Duong, Connie P M -- Poirier-Colame, Vichnou -- Roux, Antoine -- Becharef, Sonia -- Formenti, Silvia -- Golden, Encouse -- Cording, Sascha -- Eberl, Gerard -- Schlitzer, Andreas -- Ginhoux, Florent -- Mani, Sridhar -- Yamazaki, Takahiro -- Jacquelot, Nicolas -- Enot, David P -- Berard, Marion -- Nigou, Jerome -- Opolon, Paule -- Eggermont, Alexander -- Woerther, Paul-Louis -- Chachaty, Elisabeth -- Chaput, Nathalie -- Robert, Caroline -- Mateus, Christina -- Kroemer, Guido -- Raoult, Didier -- Boneca, Ivo Gomperts -- Carbonnel, Franck -- Chamaillard, Mathias -- Zitvogel, Laurence -- R01 CA161879/CA/NCI NIH HHS/ -- New York, N.Y. -- Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Institut de Cancerologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France. INSERM U1015, GRCC, Villejuif, France. University of Paris Sud XI, Kremlin-Bicetre, France. ; Institut National de la Recherche Agronomique (INRA), Micalis-UMR1319, 78360 Jouy-en-Josas, France. ; University of Lille, CNRS, INSERM, Centre Hospitalier Regional Universitaire de Lille, Institut Pasteur de Lille, U1019, UMR 8204, Centre d'Infection et d'Immunite de Lille (CIIL), F-59000 Lille, France. ; Institut de Cancerologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France. INSERM U1015, GRCC, Villejuif, France. Center of Clinical Investigations in Biotherapies of Cancer 1428, Villejuif, France. ; Institut de Cancerologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France. INSERM U1015, GRCC, Villejuif, France. University of Paris Sud XI, Kremlin-Bicetre, France. Center of Clinical Investigations in Biotherapies of Cancer 1428, Villejuif, France. ; Institut de Cancerologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France. INSERM U1015, GRCC, Villejuif, France. Universite Paris Descartes, Sorbonne Paris Cite, Paris, France. ; Department of Radiation Oncology, New York University, New York, NY, USA. ; Microenvironment and Immunity Unit, Institut Pasteur, Paris, France. ; Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore. ; Department of Genetics and Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA. ; Institut de Cancerologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France. Universite Paris Descartes, Sorbonne Paris Cite, Paris, France. Metabolomics Platform, GRCC, Villejuif, France. ; Animalerie Centrale, Institut Pasteur, Paris, France. ; Centre National de la Recherche Scientifique, Institut de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France. Universite de Toulouse, Universite Paul Sabatier, IPBS, F-31077 Toulouse, France. ; Institut de Cancerologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France. ; Institut de Cancerologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France. INSERM U1015, GRCC, Villejuif, France. Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. ; Service de microbiologie, GRCC, Villejuif, France. ; Institut de Cancerologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France. Laboratory of Immunomonitoring in Oncology, UMS 3655 CNRS/US 23 INSERM, GRCC, Villejuif, France. ; Institut de Cancerologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France. Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. INSERM U981, GRCC, Villejuif, France. ; Institut de Cancerologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France. Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. ; Universite Paris Descartes, Sorbonne Paris Cite, Paris, France. Metabolomics Platform, GRCC, Villejuif, France. INSERM U848, Villejuif, France. Equipe 11 Labellisee-Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Paris, France. Pole de Biologie, Hopital Europeen Georges Pompidou, Assistance Publique-Hopitaux de Paris, Paris, France. ; Unite des Rickettsies, Faculte de Medecine, Universite de la Mediterranee, Marseille, France. ; Institut Pasteur, Unit of Biology and Genetics of the Bacterial Cell Wall, Paris, France. INSERM, Equipe Avenir, Paris, France. ; University of Paris Sud XI, Kremlin-Bicetre, France. Gastroenterology Department, Hopital Bicetre, Assistance Publique-Hopitaux de Paris, Paris, France. ; Institut de Cancerologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805 Villejuif, France. INSERM U1015, GRCC, Villejuif, France. University of Paris Sud XI, Kremlin-Bicetre, France. Center of Clinical Investigations in Biotherapies of Cancer 1428, Villejuif, France. laurence.zitvogel@gustaveroussy.fr.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/26541610" target="_blank"〉PubMed〈/a〉
    Keywords: Adult ; Aged ; Aged, 80 and over ; Animals ; Anti-Bacterial Agents/pharmacology ; Antibodies, Monoclonal/adverse effects/*therapeutic use ; Bacteroides/*immunology ; CTLA-4 Antigen/*antagonists & inhibitors/immunology ; Dysbiosis/immunology ; Fecal Microbiota Transplantation ; Female ; Gastrointestinal Microbiome/drug effects/*immunology ; Germ-Free Life/immunology ; Humans ; Immunologic Memory ; Immunotherapy ; Intestines/immunology/microbiology ; Male ; Melanoma/*therapy ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Skin Neoplasms/*therapy ; T-Lymphocytes/immunology
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Published by American Association for the Advancement of Science (AAAS)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 10
    facet.materialart.
    Unknown
    Predictors of responses to immune checkpoint blockade in advanced melanoma (2017)
    Springer Nature
    Details
    Publication Date: 2017-09-20
    Description: Predictors of responses to immune checkpoint blockade in advanced melanoma Nature Communications, Published online: 19 September 2017; doi:10.1038/s41467-017-00608-2 The clinical management of metastatic melanoma requires predictors of the response to checkpoint blockade. Here, the authors use immunological assays to identify potential prognostic/predictive biomarkers in circulating blood cells and in tumor-infiltrating lymphocytes from patients with resected stage III melanoma.
    Electronic ISSN: 2041-1723
    Topics: Biology , Chemistry and Pharmacology , Natural Sciences in General , Physics
    Published by Springer Nature
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...